Orion

39,93EUR +1,04 %
12.857 investorer følger denne virksomhed

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo.

P/E (23e)
28,7
EV/EBIT (23e)
21,47
P/B (23e)
6,38
Udbytteafkast, % (23e)
4,26 %
Kursmål
45.00 EUR
Anbefaling
Reducer
Opdateret
27.4.2023
NASDAQ Helsinki
ORNBV
Daglig lav / høj pris
39,35 / 39,96 EUR
Markedsværdi
4,28 mia. EUR
Aktieomsætning
3,83 mio. EUR
Volumen
96 t
Risiko og anbefaling
HøjRisikoLav
SælgAnbefalingKøb

Resultatopgørelse

20192020202120222023e2024e2025e2026e
Omsætning1.051,001.078,101.041,101.340,601.181,281.290,461.418,481.517,77
vækst-%7,52 %2,58 %-3,43 %28,77 %-11,88 %9,24 %9,92 %7,00 %
EBITDA308,90336,50289,04486,60298,69330,77374,51425,87
EBIT (adj.)252,80280,10243,34439,60248,09292,94336,18387,03
EBIT252,80280,10243,34439,60248,09292,94336,18387,03
Overskud før skat250,84278,30242,34440,30247,00291,89334,11384,49
Netto indkomst200,36219,85193,79349,50195,41230,60263,95303,75
EPS (adj.)1,421,571,382,491,391,641,882,16
vækst-%1,54 %9,91 %-11,85 %80,35 %-44,09 %18,01 %14,46 %15,08 %
Udbytte1,501,501,501,601,701,801,902,00
Udbytte ratio105,33 %95,84 %108,72 %64,30 %122,20 %109,64 %101,11 %92,49 %

Profitability and return on capital

20192020202120222023e2024e2025e2026e
EBITDA-%29,39 %31,21 %27,76 %36,30 %25,29 %25,63 %26,40 %28,06 %
EBIT-% (adj.)24,05 %25,98 %23,37 %32,79 %21,00 %22,70 %23,70 %25,50 %
EBIT-%24,05 %25,98 %23,37 %32,79 %21,00 %22,70 %23,70 %25,50 %
ROE25,81 %29,11 %26,81 %43,08 %21,87 %26,37 %30,13 %33,75 %
ROI29,52 %34,41 %29,54 %45,56 %24,33 %31,05 %33,69 %36,97 %

Værdiansættelse

20192020202120222023e2024e2025e2026e
Share price (EUR)41,2737,5336,5251,2439,9339,9339,9339,93
Aktier140,70140,46140,46140,46140,46140,46140,46140,46
Markedsværdi5.806,505.271,575.129,707.197,315.608,685.608,685.608,685.608,68
Enterprise value5.667,505.085,784.940,347.078,715.327,545.354,755.369,135.342,60
EV/S5,394,724,755,284,514,153,793,52
EV/EBITDA18,3515,1117,0914,5517,8416,1914,3412,55
EV/EBIT (adj.)22,4218,1620,3016,1021,4718,2815,9713,80
EV/EBIT22,4218,1620,3016,1021,4718,2815,9713,80
P/E (adj.)28,9823,9826,4720,5928,7024,3221,2518,46
P/E28,9823,9826,4720,5928,7024,3221,2518,46
P/B7,457,217,187,936,386,446,366,11
P/S5,524,894,935,374,754,353,953,70
Udbytteprocent3,63 %4,00 %4,11 %3,12 %4,26 %4,51 %4,76 %5,01 %
Equity ratio75,25 %65,56 %66,03 %60,39 %68,60 %64,66 %62,18 %62,74 %
Gearing ratio-17,83 %-25,41 %-26,51 %-13,06 %-32,00 %-29,17 %-27,17 %-28,97 %

Kvartalsdata

Q2/22Q3/22Q4/222022Q1/23Q2/23eQ3/23eQ4/23e2023e
Omsætning283,70491,80294,501.340,60277,90290,93282,28330,171.181,28
EBITDA93,60256,7853,23486,6067,6776,8172,0882,14298,69
EBIT82,00245,4040,70439,6055,4764,0159,2869,34248,09
Overskud før skat83,10244,6040,50440,3055,1363,7659,0369,09247,00
Netto indkomst66,10194,4031,70349,5043,8350,3746,6354,58195,41
Orion Group Interim Report 1–3/2023

Selskabsmeddelelse27.04.2023